Immunovant, Inc. (IMVT)

Immunovant Income Statement

Financials in millions USD. Fiscal year is April - March.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	57.28	48.02	54.23	39.51	18.15
Research & Development	212.93	160.26	101.81	68.6	47.93
Other Operating Expenses	12.5	10	0	0	0
Operating Expenses	282.71	218.28	156.03	108.12	66.08
Operating Income	-282.71	-218.28	-156.03	-108.12	-66.08
Interest Expense / Income	0	0	0	0	0.63
Other Expense / Income	-23.94	-7.33	0.78	-0.33	-0.41
Pretax Income	-258.77	-210.95	-156.81	-107.79	-66.29
Income Tax	0.57	0.01	-0.08	-0.36	0.1
Net Income	-259.34	-210.96	-156.73	-107.43	-66.39
Shares Outstanding (Basic)	138	123	110	88	43
Shares Outstanding (Diluted)	138	123	110	88	43
Shares Change	12.21%	12.21%	24.98%	103.14%	94.85%
EPS (Basic)	-1.88	-1.71	-1.43	-1.22	-1.54
EPS (Diluted)	-1.88	-1.71	-1.43	-1.22	-1.54
Free Cash Flow	-214.59	-188.39	-106.37	-83.54	-53.39
Free Cash Flow Per Share	-1.55	-1.53	-0.97	-0.95	-1.24
EBITDA	-257.41	-209.63	-155.58	-106.79	-65.65
Depreciation & Amortization	1.36	1.32	1.23	1	0.02
EBIT	-258.77	-210.95	-156.81	-107.79	-65.67

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).